AstraZeneca PLC
A global, science-led biopharmaceutical company developing prescription medicines.
AZN | IL
Overview
Corporate Details
- ISIN(s):
- GB0009895292 (+925 more)
- LEI:
- PY6ZZQWO2IZFZC3IOL08
- Country:
- United Kingdom
- Address:
- 1 FRANCIS CRICK AVENUE, CB2 0AA CAMBRIDGE
- Website:
- https://www.astrazeneca.com/
- Sector:
- Manufacturing
Description
AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2026-01-08 08:25 |
AZN new Head of Investor Relations Joris Silon
|
English | HTML • 7.2 KB | ||
| 2026-01-02 16:10 |
Total Voting Rights
|
English | HTML • 8.8 KB | ||
| 2026-01-02 16:00 |
Total Voting Rights
|
English | PDF • 199.4 KB | ||
| 2025-12-22 12:10 |
Director/PDMR Shareholding
|
English | HTML • 23.0 KB | ||
| 2025-12-22 09:30 |
Enhertu granted BTD for post-neoadjuvant early BC
|
English | HTML • 34.1 KB | ||
| 2025-12-22 08:20 |
Update on LATIFY Phase III trial of ceralasertib
|
English | HTML • 19.7 KB | ||
| 2025-12-19 12:10 |
Director/PDMR Shareholding
|
English | HTML • 27.4 KB | ||
| 2025-12-16 08:45 |
Subcutaneous Saphnelo approved in EU
|
English | HTML • 30.0 KB | ||
| 2025-12-16 08:25 |
Enhertu approved in US for 1L HER2+ metastatic BC
|
English | HTML • 36.8 KB | ||
| 2025-12-04 19:48 |
HOLDING(S) IN COMPANY
|
English | ZIP • 13.5 KB | ||
| 2025-12-04 16:10 |
Holding(s) in Company
|
English | HTML • 24.7 KB | ||
| 2025-12-04 09:22 | Swedish | HTML • 11.0 KB | |||
| 2025-12-01 17:47 |
BLOCK LISTING INTERIM REVIEW
|
English | ZIP • 10.4 KB | ||
| 2025-12-01 17:40 |
TOTAL VOTING RIGHTS
|
English | ZIP • 9.3 KB | ||
| 2025-12-01 16:15 |
Block listing Interim Review
|
English | HTML • 14.9 KB |
Automate Your Workflow. Get a real-time feed of all AstraZeneca PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for AstraZeneca PLC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for AstraZeneca PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-11-13 | Philip Broadley | Other | Buy | 980 | 99,665.12 EUR |
| 2024-03-08 | Pascal Soriot | Other | Other | 105,238 | N/A |
| 2024-03-05 | Pascal Soriot | Other | Other | 17,702 | N/A |
| 2024-03-04 | Pascal Soriot | Other | Other | 109,872 | 11,076,196.32 EUR |
| 2024-03-04 | Aradhana Sarin | Other | Other | 59,125 | 5,960,391.25 EUR |
| 2023-12-12 | Anna Manz | Other | Buy | 487 | 49,623.16 EUR |
| 2023-11-22 | Michel Demare | Other | Buy | 1,000 | 101,700.00 EUR |
| 2023-11-21 | Michel Demare | Other | Buy | 1,000 | 101,052.24 EUR |
| 2023-04-28 | Michel Demare | Other | Buy | 2,000 | 234,020.00 EUR |
| 2023-03-23 | Pascal Soriot | Other | Other | 138,093 | N/A |
Peer Companies
